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Introduction: Recent genome-wide association studies have identified that 
variants in PNPLA3 and TM6SF2 are significantly associated with 
nonalcoholic fatty liver disease (NAFLD) in multiple ethnic groups. However, 
the data on their genetic impact on NAFLD in Asian populations are limited. 
Therefore, we investigated the effects of PNPLA3 rs738409 and TM6SF2 
rs58542926 variants on metabolic phenotypes and their combined effects on 
the histological severity of NAFLD. 
Methods: In a biopsy-proven NAFLD cohort of 525 subjects, PNPLA3 
rs738409 and TM6SF2 rs58542926 were genotyped. Homeostasis model 
assessment of insulin resistance (HOMA-IR) and adipose tissue insulin 
resistance (adipo-IR) were calculated. 
iii 
 
Results: The rs738409 and rs58542926 variants were associated with not only 
non-alcoholic steatohepatitis (NASH) (odds ratio [OR], 2.00; 95% confidence 
interval [CI], 1.46–2.73 and OR, 1.91; 95% CI, 1.04–3.51) but also with 
significant fibrosis (≥F2) (odds ratio [OR], 1.53; 95% CI, 1.11–2.11 and OR, 
1.88; 95% CI, 1.02–3.46), even after adjustment for metabolic factors. Of 
both variants, only rs738409 was associated with HOMA-IR and adipo-IR 
even in healthy controls (P = 0.046 and 0.002, respectively) as well as in the 
entire study cohort (P = 0.016 and 0.048, respectively). PNPLA3 and TM6SF2 
risk variants additively increased the risk of NASH and significant fibrosis 
(OR per risk allele, 2.03; 95% CI, 1.50–2.73 and 1.61; 95% CI, 1.19–2.17). 
Even in subjects with low insulin resistance, the risk of NASH and significant 
fibrosis increased as the number of risk alleles increased (P = 0.008 and 0.020, 
respectively). 
Conclusions: PNPLA3 and TM6SF2 determine the risk of NASH and 
significant fibrosis, even after adjustment for insulin resistance, and exert an 
additive effect on NASH and significant fibrosis. 
---------------------------------------------------------------------------------------------- 
Keywords: Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, 
insulin resistance, PNPLA3, and TM6SF2 
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Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver 
disease in the worldwide.
1 
The prevalence of NAFLD is rapidly increasing in 
parallel with the increase in diabetes and obesity.
2
 The spectrum of NAFLD is 
diverse, ranging from simple steatosis to non-alcoholic steatohepatitis 
(NASH), which can lead to advanced fibrosis (cirrhosis). Currently, biopsy 
has been regarded as the “gold standard” for the diagnosis and assessment of 
liver fibrosis. 
 According to the clinical practice guideline, metabolic syndrome and/or 
insulin resistance can alert patients with NAFLD to the need for liver 
biopsy.
3,4
 Insulin resistance is one of the major pathophysiological 
mechanisms in the development of NAFLD
3,4
; therefore, the presence of 
metabolic syndrome can predict not only the risk of NAFLD
5
, but also the 
presence of steatohepatitis in patients with NAFLD.
6,7
 
 Currently, several genetic variants have been reported to influence on the 
risk of NAFLD with metabolic risk factors. The patatin-like phospholipase 
domain-containing-3 (PNPLA3)
8-10
 and the transmembrane 6 superfamily 
member 2 (TM6SF2)
11,12
 genes are known to increase the risk of NAFLD and 
the histologic severity of NAFLD. However, there is uncertainty regarding the 
interaction between genotypes and metabolic risk.
13-15
 
In this study, we aimed to determine whether there is an additive effect of 
genetic variants on the histologic severity of NAFLD. In addition, we 
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MATERIALS and METHODS 
 
Subjects 
We constructed a prospective cohort from the ongoing Boramae NAFLD 
registry (NCT 02206841) at the Seoul Metropolitan Government Seoul 
National University Boramae Medical Center. The details of eligibility criteria 
and liver biopsy indication were previously reported.
16
 Briefly, the inclusion 
criteria of this study were as follows: (i) ≥18 years old; (ii) bright liver 
echogenicity observed upon ultrasound scanning; and (iii) unexplained high 
levels of alanine aminotransferase (ALT) above the upper reference level 
within the past 6 months.
17
 The following conditions were excluded from this 
study: (i) viral hepatitis, e.g., hepatitis B or C; (ii) autoimmune hepatitis; (iii) 
drug-induced liver injury or steatosis; (iv) Wilson disease or hemochromatosis; 
and (v) excessive alcohol intake (male >30 g/day, female >20 g/day),
3
 and (vi) 
diagnosis of malignancy within the past year. Of the eligible study participants, 
those with clinically suspected NASH or fibrosis
18
 underwent liver biopsy. 
For comparison, control liver tissues were collected from subjects who 
underwent liver biopsy in a pre-evaluation for donor liver transplantation or in 
a characterization of solid liver masses that were suspected to be hepatic 
adenoma or focal nodular hyperplasia based on radiological results without 
any evidence of hepatic steatosis. This is a single center-based cohort, and the 
participants were all Asians. 
 This study was approved by the Institutional Review Board of Boramae 
４ 
 
Medical Center (IRB No.16-2014-86) and complied with the 1975 Helsinki 
Declaration. Informed consent was obtained from all the patients who 
participated in this study. 
 
Clinical and laboratory assessment 
Based on the World Health Organization (WHO) Asia‒Pacific criteria
19
, 
Obesity is defined as a body mass index (BMI) ≥25 kg/m
2
 and ≥30 kg/m
2
 
indicated a more severe form of obesity (class II obesity). Metabolic 
syndrome was defined based on the revised National Cholesterol Education 
Program Adult Treatment Panel III (NCEP-ATP III) criteria
20
, as the presence 
of at least 3 of the following 5 components: abdominal obesity (waist 
circumference ≥90 cm for men and ≥80 cm for women
21
), blood pressure 
≥130/85 mmHg, triglyceride ≥150 mg/dL, high-density lipoprotein (HDL) 
cholesterol <40 mg/dL in men and <50 mg/dL in women, and elevated blood 
glucose levels and fasting blood glucose ≥100 mg/dL. Diabetes mellitus was 
defined as fasting plasma glucose levels of ≥126 mg/dL, glycosylated 
hemoglobin (HbA1c) levels of ≥6.5% and/or treatment with anti-diabetic 
medication at the time of the survey
22
. Hypertension was defined as systolic 
blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg and/or the 




 Venous blood samples were drawn at the time of biopsy after a 12-hr 
overnight fasting state, and plasma was separated immediately via 
centrifugation. The plasma glucose and lipid concentrations were measured 
５ 
 
enzymatically using the Hitachi Automatic Analyzer B2400 (Hitachi, Tokyo, 
Japan). Fasting insulin levels were measured using immune radiometric 
assays (DIAsource ImmunoAssays, Nivelles, Belgium). Hepatic insulin 
resistance was indirectly evaluated using the homeostasis model assessment 
of insulin resistance (HOMA-IR), as described previously
25
. HOMA-IR ≥2.5 
was considered to indicate insulin resistance
26,27
. Adipose insulin resistance 
(Adipo-IR) was calculated as [fasting plasma free fatty acid level (μEq/L) × 





Liver biopsy specimens were fixed in 4%-buffered formalin and embedded in 
paraffin. Two-micrometer-thick sections were stained with hematoxylin-eosin 
and Masson’s trichrome.  
All biopsy specimens were analyzed by an experienced pathologist who was 
blinded to the clinical results of the patients. NAFLD was defined as the 
presence of ≥5% macrovesicular steatosis30; and NASH was diagnosed based 
on an overall pattern of histological hepatic injury consisting of 
macrovesicular steatosis, inflammation, or hepatocellular ballooning 
according to Brunt et al.’s criteria
30,31
. Fibrosis was assessed according to a 5-
point scale proposed by Brunt and modified by Kleiner et al. as follows: F0, 
absence of fibrosis; F1, perisinusoidal or periportal fibrosis; F2, perisinusoidal 
and portal/periportal fibrosis; F3, bridging fibrosis; and F4, cirrhosis.
32
 
Significant fibrosis was defined as ≥F2. We excluded patients with biopsy 
６ 
 
lengths that were less than 20 mm, as well as those with biopsies of fewer 
than eight portal tracts.  
 
Genotyping 
Established risk alleles for NAFLD from the previous studies were selected 
for genotyping; the rs738409 C>G (I148M PNPLA3)
8-10
, and rs58542926 C>T 
(E167K, TM6SF2)
11,12
 single-nucleotide polymorphisms (SNPs) were 
genotyped in the entire cohort by TaqMan 5’-nuclease assays (Life 
Technologies, Carlsbad, CA, USA) according to the manufacturer’s 




Descriptive values are presented as the frequency (percentage) and the median 
(IQR). Continuous variables were analyzed using the Student t-test or the non-
parametric Mann-Whitney U test. Three independent groups were compared 
using one-way analysis of variance (ANOVA) or the Kruskal-Wallis test. 
Categorical variables were analyzed using the chi-square test or Fisher’s exact 
test. To investigate the independent determining factors for the presence of 
significant fibrosis or NASH, a binary logistic regression model adjusted for 
covariates was generated. The generalized linear model or the linear-by-linear 
association test was used to identify the trends in metabolic phenotype or 
histological severity according to genotypes.  
７ 
 
The odds of the significant fibrosis or NASH per risk allele was estimated by 
logistic regression models and adjusted for age and sex. Genetic analyses 
were performed assuming an additive model (by coding the genotypes as 0, 1, 
and 2 for wild-type homozygotes, heterozygotes, and alternate allele 
homozygotes, respectively) or a dominant model for (by coding the genotypes 
as 0 and 1 for wild-type homozygotes and [heterozygotes + alternate allele 
homozygotes], respectively) considering minor allele frequency (MAF). 
Statistical analyses were performed using the IBM SPSS Statistics software 
package version 20.0 (IBM Inc., Armonk, NY, USA). P values less than 0.05 





Clinical characteristics of the study population 
Among the 416 subjects (mean age, 52.6 ± 15.5 years), 204 (49%) and 212 
(51%) subjects were classified as biopsy-proven NASH and NAFL, 
respectively (Table 1). We compared their clinical characteristics with those of 
control subjects (n = 109; mean age, 55.5 ± 13.8 years). As the severity of 
NAFLD increased, BMI and waist circumference increased along with 
increasing trends in HOMA-IR, adipo-IR, and serum hsCRP levels (P < 
0.001). The prevalence of diabetes mellitus, hypertension, metabolic 
syndrome, and obesity increased as the severity of NAFLD increased (all P < 
0.001; Table 1). 
 HOMA-IR, adipo-IR, and serum hsCRP levels were also significantly 
higher in NASH subjects than in NAFL subjects (all P < 0.001; Table 1); 
however, blood pressure, fasting glucose levels, and lipid profiles were not 
significantly different between NAFL and NASH groups (Table 1). Subjects 
with NAFL showed prevalence of diabetes (38.1% vs. 47.0%), hypertension 
(50.9% vs. 58.3%), obesity (BMI ≥25 kg/m
2
; 73.6% vs. 78.3%), metabolic 
syndrome (70.2% vs. 81.0%) similar to those in patients with NASH (Table 1). 
Statistically, only class II obesity (BMI ≥30 kg/m
2
; odds ratio (OR), 1.96; 95% 
CI, 1.23–3.13), metabolic syndrome (OR, 1.62; 95% CI 1.01–2.61), insulin 
resistance (OR, 2.61; 95% CI, 1.63–4.17), and high CRP levels (OR, 2.97; 95% 
CI, 1.95–4.51) were more frequently observed in NASH than in NAFL after 
９ 
 
adjustment for age and sex; however, obesity (BMI ≥25 kg/m
2
), hypertension, 
and diabetes were not significantly different between both groups (Table 2). 
 













Age, years 55.5 ± 13.8 51.8 ± 14.7 53.5 ± 16.2 0.111 0.260 



















SBP, mmHg 122.7 ± 14.5 129.6 ± 15.5 131.0 ± 17.8 <0.001 0.374 
DBP, mmHg 75.0 ± 10.5 80.0 ± 12.2 79.7 ± 12.0 0.001 0.800 
Total cholesterol, 
mg/dL 
177.3 ± 40.6 183.8 ± 40.2 183.0 ± 39.5 0.367 0.843 
HDL cholesterol, 
mg/dL 

































Albumin, g/dL 4.1 ± 0.4 4.2 ± 0.3 4.2 ± 0.3 0.002 0.281 
Platelet, x10
9































hsCRP, mg/dL 0.6 (0.3, 1.5) 0.9 (0.5, 1.7) 1.6 (0.8, 3.3) <0.001 <0.001 
Diabetes, N (%) 18 (17.0) 80 (38.1) 94 (47.0) <0.001 0.068 
Hypertension, N (%) 39 (35.8) 108 (50.9) 119 (58.3) <0.001 0.130 
Obesity (BMI ≥ 25), N 
(%) 
34 (31.2) 156 (73.6) 159 (78.3) <0.001 0.259 
Obesity II (BMI ≥ 30), 
N (%) 





40 (36.7) 146 (70.2) 162 (81.0) <0.001 0.011 
 
The data are expressed as the means ± standard deviations or medians (interquartile 
ranges) 
1
P-values from ANOVA, the Kruskal-Wallis test or χ
2
 test to compare the subjects with 
no NAFLD, NAFL, and NASH.  
2
P-values from independent T-test, the Mann-Whitney test or χ
2
 test to compare 
subjects with NAFL and NASH. 
 
Abbreviations: NAFLD, non-alcoholic fatty liver disease; NAFL, non-alcoholic fatty 
liver; NASH, non-alcoholic steatohepatitis; BMI, body mass index; WC, waist 
circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-
density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
GGT, gamma-glutamyl transferase; HOMA-IR, homeostasis model assessment of 
insulin resistance; hsCRP, high sensitivity C-reactive protein. 
 
Table 2. The risk of NASH or significant fibrosis according to obesity, 
metabolic status 
  Odds ratio (95% CI)
1
 P-value 
Odds ratio for NAFLD in the entire cohort (N = 525)  
BMI ≥ 25 kg/m
2
 6.84 (4.27, 10.94) <0.001 
BMI ≥ 30 kg/m
2
 6.53 (2.75, 15.50) <0.001 
Metabolic syndrome 6.80 (4.19, 11.03) <0.001 
Diabetes mellitus 4.77 (2.68, 8.49) <0.001 
Insulin resistance (HOMA-IR ≥2.5) 6.62 (4.13, 10.60) <0.001 
High hsCRP level (hsCRP ≥ 1mg/dL) 2.76 (1.76, 4.33) <0.001 
   
Odds ratio for NASH in NAFLD subjects (N = 416)  
BMI ≥ 25 kg/m
2
 1.36 (0.85, 2.18) 0.196 
BMI ≥ 30 kg/m
2
 1.96 (1.23, 3.13) 0.005 
Metabolic syndrome 1.62 (1.01, 2.61) 0.045 
Diabetes mellitus 1.45 (0.94, 2.22) 0.092 
Insulin resistance (HOMA-IR ≥2.5) 2.61 (1.63, 4.17) <0.001 
High hsCRP level (hsCRP ≥ 1mg/dL) 2.97 (1.95, 4.51) <0.001 
   
Odds ratio for Significant fibrosis in NAFLD subjects (N = 416)  
BMI ≥ 25 kg/m
2
 1.11 (0.68, 1.82) 0.672 
BMI ≥ 30 kg/m
2
 1.51 (0.92, 2.48) 0.107 
Metabolic syndrome 1.19 (0.70, 2.00) 0.526 
Diabetes mellitus 2.16 (1.38, 3.40) 0.001 
Insulin resistance (HOMA-IR ≥2.5) 2.39 (1.40, 4.07) 0.001 
High hsCRP level (hsCRP ≥ 1mg/dL) 2.64 (1.68, 4.17) <0.001 
   
1
From age and sex-adjusted logistic analysis  
１１ 
 
Abbreviations: NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic 
steatohepatitis; BMI, body mass index; HOMA-IR, homeostasis model assessment of 
insulin resistance; hsCRP, high sensitivity C-reactive protein. 
  
Approximately one third of NAFLD subjects (141/416, 33.9%) had 
significant fibrosis. Subjects with significant fibrosis had higher HOMA-IR, 
adipo-IR, and serum hsCRP levels than those without significant fibrosis (P < 
0.001 for all comparisons; Table 3). With adjustment for age and sex, diabetes 
(OR, 2.16; 95% CI, 1.38–3.40), insulin resistance (OR, 2.39; 95% CI, 1.40–
4.07), and high CRP levels (OR, 2.64; 95% CI, 1.68–4.17) showed a 
statistically significant association with significant fibrosis in NAFLD 
subjects. Metabolic syndrome and class II obesity were not significantly 
associated with significant fibrosis in NAFLD subjects (Table 2). 
 
Table 3. Characteristics of study participants according to significant 







Age, years 49.8 ± 15.6 58.0 ± 13.8 <0.001 
Male, N (%) 163 (59.3) 55 (39.0) <0.001 
BMI, kg/m
2
 27.4 (25.1, 30.4) 27.0 (24.9, 30.9) 0.844 
WC, cm 91.9 (86.4, 99.1) 91.9 (86.7, 101.0) 0.396 
SBP, mmHg 130.6 ± 15.8 129.6 ± 18.1 0.569 
DBP, mmHg 80.6 ± 11.6 78.3 ± 12.7 0.067 
Total cholesterol, mg/dL 186.6 ± 37.3 177.1 ± 43.7 0.029 
HDL cholesterol, mg/dL 43.5 (37.0, 52.0) 44.0 (35.0, 52.0) 0.525 
Triglycerides, mg/dL 142.0 (107.0, 193.0) 139.0 (91.0, 188.5) 0.166 
ALT, IU/L 40.0 (25.0, 74.0) 57.0 (31.0, 91.5) 0.001 
AST, IU/L 33.0 (24.0, 49.0) 52.0 (36.5, 75.5) <0.001 
GGT, IU/L 37.0 (22.0, 63.0) 56.0 (36.0, 104.0) <0.001 
１２ 
 
Albumin, g/dL 4.2 ± 0.3 4.1 ± 0.3 <0.001 
Platelet, x10
9
/L 244 ± 55 201 ± 71 <0.001 
Glucose, mg/dL 104.0 (93.0, 117.0) 112.0 (98.0, 140.0) <0.001 
Insulin, μIU/mL 12.1 (9.2, 16.5) 16.0 (11.0, 23.5) <0.001 
HOMA-IR 3.23 (2.35, 4.47) 4.67 (3.04, 7.90) <0.001 
Adipo-IR  7205 (4899, 11560) 11485 (7107, 17770) <0.001 
hsCRP, mg/dL 1.0 (0.5, 2.2) 1.5 (0.9, 3.5) <0.001 
Diabetes, N (%) 92 (33.9) 82 (59.0) <0.001 
Obesity (BMI ≥ 25), N (%) 211 (76.7) 104 (74.3) 0.582 
Obesity (BMI ≥ 30), N (%) 73 (26.5) 40 (28.6) 0.661 
Metabolic syndrome, N (%) 198 (73.1) 110 (80.3) 0.109 
The data are expressed as the means ± standard deviations or medians (interquartile 
ranges) 
1
P-values from independent T-test, the Mann-Whitney test or χ
2
 test to compare 
subjects with F0-1 vs. F2-4 
 
Abbreviations: BMI, body mass index; WC, waist circumference; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl 
transferase; HOMA-IR, homeostasis model assessment of insulin resistance; Adipo-IR, 
adipose tissue insulin resistance; hsCRP, high sensitivity C-reactive protein. 
 
Association between genetic variants and NASH or 
significant fibrosis independent of insulin resistance 
The genotypic distributions of PNPLA3 rs738409, and TM6SF2 rs58542926 
were in Hardy–Weinberg equilibrium (P = 0.33, and 0.91, respectively). The 
minor allele frequencies (MAFs) of the SNPs in the set of all subjects were 
0.51 for PNPLA3 rs738409 (0.38 in subjects with no NAFLD and 0.54 in 
those with NAFLD; P < 0.001), 0.08 for TM6SF2 rs58542926 (0.05 for no 




Table 4. Distribution of genotypes and minor allele frequencies according 
to NAFLD status 
 
  No NAFLD NAFL NASH Minor allele frequency  









rs738409 PNPLA3        
CC 34 (35.8) 62 (32.8) 23 (13.1) 0.51 0.38 0.54 <0.001 
CG 50 (52.6) 82 (43.4) 82 (46.6)     
GG 11 (11.6) 45 (23.8) 71 (40.3)     
        
rs58542926 TM6SF2       
CC 87 (90.6) 166 (87.8) 140 (79.5) 0.08 0.05 0.08 0.088 
CT 9 (9.4) 23 (12.2) 34 (19.3)     
TT 0 0 2 (1.1)     




comparing the minor allele frequency between No NAFLD and 
NAFLD  
Abbreviations: NAFLD, non-alcoholic fatty liver disease; NAFL, non-alcoholic fatty 
liver; NASH, non-alcoholic steatohepatitis. 
 
The number of G alleles at PNPLA3 rs738409 was positively correlated with 
the histological grades of steatosis, lobular inflammation, and hepatocellular 
ballooning (P < 0.001, P = 0.001, and P < 0.001 for trend, respectively) and 
fibrosis stage (P < 0.001 for trend) (Figure 1). In the case of TM6SF2 
rs58542926, we compared the histology between the CC and CT/TT 
genotypes considering the MAF: only 2 subjects were TT homozygous (Table 
4). The presence of the T allele at TM6SF2 rs58542926 was not significantly 
associated with steatosis grade (P for trend = 0.377); however, it significantly 
increased the severity of lobular inflammation (P for trend = 0.041) and 




Figure 1. Histologic severity according to PNPLA3 genotype 
 
 





Among NAFLD subjects, both PNPLA3 rs738409 and TM6SF2 rs58542926 
were significantly associated with the risk of NASH or significant fibrosis 
(Table 5). 
An additive model for PNPLA3 rs738409 and dominant model for TM6SF2 
rs58542926 were assumed considering the MAF and the histological severity 
of NAFLD according to the genotype. We replicated the associations between 
NASH and both genetic variants in NAFLD subjects: both PNPLA3 rs738409 
and TM6SF2 rs58542926 were associated with the risk of NASH in NAFLD 
subjects, even after adjustment for age and sex (OR for rs734809, 1.97; 95% 
CI, 1.46–2.66; P < 0.001 and OR for rs58542926, 1.86; 95% CI, 1.04–3.32; P 
= 0.035; Model 2 in Table 6). 
 We found that additional adjustment for metabolic syndrome, obesity, and 
insulin resistance did not attenuate the significant associations between both 
variants and NASH or significant fibrosis in NAFLD subjects (Model 5 in 





Table 5. Risk of NAFLD, NASH, and significant fibrosis according to the genotype 
 
  Odds ratio for NAFLD Odds ratio for NASH in NAFLD Odds ratio for ≥F2 in NAFLD 
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value 
rs738409 PNPLA3        
Additive 1.88 (1.34, 2.60) <0.001 2.00 (1.49, 2.69) <0.001 1.64 (1.21, 2.22) 0.002 
Dominant  1.84 (1.13, 2.98) 0.014 3.25 (1.91, 5.54) <0.001 1.95 (1.12, 3.40) 0.019 
Recessive 3.56 (1.83, 6.92) <0.001 2.16 (1.38, 3.39) 0.001 1.96 (1.24, 3.09) 0.004 
       
rs58542926 TM6SF2       
Additive 1.88 (0.91, 3.88) 0.089 1.90 (1.10, 3.29) 0.022 1.73 (1.01, 2.97) 0.045 
Dominant  1.86 (0.89, 3.91) 0.099 1.86 (1.05, 3.28) 0.033 1.79 (1.02, 3.15) 0.044 
Recessive –  0.999 – 0.999 1.93 (0.12, 31.1) 0.644 
       
Without adjustment 












Table 6. Risk of NAFL, NASH, and significant fibrosis according to the genotype with adjustment for metabolic risk factors 
 
   Odds ratio for NAFLD (95% CI) Odds ratio for NASH in NAFLD
 
(95% CI) Odds ratio for ≥F2 in NAFLD
 
(95% CI) 
 Odds ratio (95% CI) P value Odds ratio (95% CI) P value Odds ratio (95% CI) P value 
rs738409 in PNPLA3
1







1.88 (1.34, 2.60) 
1.96 (1.41, 2.71) 
2.07 (1.49, 2.69) 
1.96 (1.37, 2.80) 





  0.001 
2.00 (1.49, 2.69) 
1.97 (1.46, 2.66) 
1.98 (1.46, 2.69) 
1.94 (1.43, 2.80) 







1.64 (1.21, 2.22) 
1.54 (1.13, 2.11) 
1.53 (1.12, 2.10) 
1.50 (1.09, 2.06) 














1.86 (0.89, 3.91) 
1.84 (0.87, 3.88) 
1.91 (0.86, 4.21) 
1.97 (0.88, 4.41) 






1.86 (1.05, 3.28) 
1.86 (1.04, 3.32) 
1.92 (1.06, 3.48) 
1.89 (1.04, 3.44) 






1.79 (1.02, 3.15) 
1.90 (1.05, 3.44) 
1.87 (1.03, 3.42) 
1.86 (1.02, 3.40) 






       
Model 1, without adjustment 
Model 2, with adjustment for age and sex 
Model 3, with adjustment for age, sex, and metabolic syndrome 
Model 4, with adjustment for BMI ≥ 30 kg/m
2
 in addition to model 3 
Model 5, with adjustment for HOMA-IR in addition to model 4 
1
Additive model; odds ratio for the number of risk allele (G) 
2
Dominant model; odds ratio for CT/TT genotype 
 




In addition, stratified analysis according to insulin resistance showed that 
even in subjects with HOMA-IR <2.5, the presence of a risk allele (G) 
increased the risk of NASH in a dose-dependent manner (Figure 3a). As the 
number of G alleles at PNPLA3 rs738409 increased, the risk of NASH 
increased in NAFLD subjects with HOMA-IR <2.5, even after adjustment for 
age and sex (OR per risk allele, 2.52; 95% CI, 1.26–5.03; Table 7). Among 
NAFLD subjects, the risk of NASH in subjects with both HOMA-IR ≥2.5 and 
GG genotype increased by as much as 20 times compared to that in subjects 
with the CC genotype and HOMA-IR <2.5 (OR, 20.64; 95% CI, 4.47 –95.21; 
Table 7), implicating that genetic variants affected the histological severity of 
NAFLD in addition to insulin resistance. The number of risk alleles (G) 
tended to be positively related with the prevalence of significant fibrosis, even 
in subjects with HOMA-IR <2.5 (Figure 3b), although the relationship was 
not statistically significant (OR per risk allele, 2.01; 95% CI, 0.97–4.17; P = 
0.062). 
 In the case of TM6SF2 rs58542926, similar trends were noticed after 
stratification according to insulin resistance among NAFLD subjects (Figure 
3c-d); however, risk variants at TM6SF2 rs58542926 were not a significant 
risk factor for NASH or significant fibrosis in subjects with low insulin 





Figure 3. Additive effects of genetic variants and insulin resistance on the 
risk of NASH and significant fibrosis in subjects with NAFLD 
(a–b) Prevalence of NASH and significant fibrosis among NAFLD subjects according to 
the genotype at PNPLA3 rs738409 stratified by HOMA-IR is shown (c–d) Prevalence 
of NASH and significant fibrosis among NAFLD subjects according to the genotype at 
TM6SF2 rs58542926 stratified by HOMA-IR is shown. 
*
P < 0.05 compared to subjects 
with HOMA-IR < 2.5 and the CC genotype (with adjustment for age and sex). 
†
P < 
0.05 compared to subjects with HOMA-IR ≥ 2.5 and the CC genotype (with 
adjustment for age and sex). 
‡
P < 0.05 compared to subjects with the same number 
of risk alleles and no metabolic risk factors (with adjustment for age and sex).
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Table 7. The risk of NASH or significant fibrosis according to PNPLA3 genotype and metabolic phenotype among NAFLD subjects 
  Odds ratio (95% CI)
1
 P-value Odds ratio (95% CI)
1
 P-value Odds ratio (95% CI)
1
 P-value 
Odds ratio for NASH according to PNPLA3 genotype & insulin resistance    
        
HOMA-IR<2.5 CC at rs738409 (reference) –          
 CG at rs738409 5.25 (1.07, 25.66) 0.041   Per risk allele  
 GG at rs738409 8.43 (1.63, 43.54) 0.011   2.52 (1.26, 5.03) 0.009 
HOMA-IR≥2.5 CC at rs738409 5.36 (1.13, 25.32) 0.034 (reference) –   
 CG at rs738409 13.75 (3.06, 61.85) 0.001 2.58 (1.35, 4.93) 0.004 Per risk allele  
 GG at rs738409 20.64 (4.47, 95.21) <0.001 3.87 (1.92, 7.78) <0.001 1.93 (1.37, 2.74) <0.001 
        
Odds ratio for significant fibrosis according to PNPLA3 genotype & insulin resistance    
        
HOMA-IR<2.5  CC at rs738409 (reference) –     
 CG at rs738409 1.21 (0.28, 5.24) 0.797   Per risk allele  
 GG at rs738409 3.14 (0.73, 13.51) 0.125   2.01 (0.97, 4.17) 0.062 
HOMA-IR≥2.5 CC at rs738409 2.14 (0.55, 8.39) 0.275 (reference) –   
 CG at rs738409 3.96 (1.08, 14.46) 0.038 1.87 (0.93, 3.78) 0.080 Per risk allele  
 GG at rs738409 4.98 (1.34, 18.55) 0.017 2.33 (1.12, 4.85) 0.023 1.49 (1.05, 2.13) 0.028 
        
1
From age and sex-adjusted logistic analysis  
Abbreviations: NAFLD, non-alcoholic fatty liver disease; HOMA-IR, homeostasis model assessment of insulin resistance.
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Table 8. The risk of NASH or significant fibrosis according to TM6SF2 genotype and metabolic phenotype among NAFLD subjects 
 
  Odds ratio (95% CI)
1
 P-value Odds ratio (95% CI)
1
 P-value 
Odds ratio for NASH according to TM6SF2 genotype & insulin resistance  
      
HOMA-IR<2.5 CC at rs58542926 (reference) –   
 CT/TT at rs58542926 1.47 (0.47, 4.57) 0.505   
HOMA-IR≥2.5 CC at rs58542926 2.56 (1.47, 4.43) 0.001 (reference) – 
 CT/TT at rs58542926  5.45 (2.41, 12.34) <0.001 2.13 (1.05, 4.33) 0.037 
      
Odds ratio for significant fibrosis according to TM6SF2 genotype & insulin resistance  
      
HOMA-IR<2.5 CC at rs58542926 (reference) –   
 CT/TT at rs58542926 2.44 (0.75, 7.99) 0.139   
HOMA-IR≥2.5 CC at rs58542926 2.43 (1.30, 4.56) 0.006 (reference) – 
 CT/TT at rs58542926  4.39 (1.88, 10.23) 0.001 1.82 (0.91, 3.65) 0.092 
      
1
From age and sex-adjusted logistic analysis  
Abbreviations: NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; HOMA-IR, homeostasis model assessment of insulin resistance 
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Additive effect of PNPLA3 and TM6SF2 variants on the 
risk of NASH and significant fibrosis  
Comparing the metabolic profiles across PNPLA3 rs738409 and TM6SF2 
rs58542926 variants, significant trend toward higher BMI, fasting glucose 
level, HOMA-IR, and adipo-IR were found as the number of G alleles at 
PNPLA3 rs738409 increased (P = 0.021, P = 0.005, P = 0.016, and P = 0.048, 
respectively; Table 9). However, TM6SF2 rs58542926 was not significantly 
associated with these metabolic traits (Table 9). To exclude the indirect effect 
of the PNPLA3 variant on these metabolic traits mediated by NAFLD, we 
retested rs738409 for confirming such association in the control subjects, and 
verified the positive associations between the number of G alleles at rs732409 
and HOMA-IR and adipo-IR even in subjects without NAFLD (P = 0.046 and 
0.002, respectively; Figure 4). However, neither BMI nor fasting glucose level 
were associated with rs738409 in the control subjects (P = 0.132 and 0.250, 
respectively). 
 












 CC (n = 119) CG (n = 214) GG (n = 127) CC (n = 393) CT/TT (n = 68) 
BMI, kg/m
2
 26.4 (23.6, 29.3) 26.5 (24.1, 29.5) 26.8 (24.9, 30.1) 0.021 26.6 (24.2, 29.4) 26.6 (23.9, 30.1) 0.621 
Total cholesterol, mg/dL 181.4 ± 38.1 183.9 ± 40.9 179.2 ± 41.8 0.824 182.9 ± 40.7 177.0 ± 36.3 0.161 
HDL cholesterol, mg/dL 46.0 (38.0, 54.0) 45.0 (38.0, 55.0) 45.0 (36.0, 53.0) 0.238 45.0 (37.5, 55.0) 46.0 (38.0, 52.0) 0.605 
Triglycerides, mg/dL 130.0 (89.0, 188.0) 129.0 (86.0, 182.3) 131.0 (94.0, 193.0) 0.090 132.0 (90.0, 186.5) 109.0 (84.3, 175.0) 0.880 
ALT, IU/L 34.0 (20.0, 54.0) 39.5 (24.0, 66.5) 39.0 (25.0, 79.0) 0.002 37.0 (23.0, 60.5) 43.0 (25.0, 96.8) 0.023 
AST, IU/L 29.0 (22.0, 44.0) 34.0 (23.8, 49.0) 40.0 (26.0, 64.0) 0.002 33.0 (24.0, 50.0) 41.0 (24.0, 58.8) 0.289 
GGT, IU/L 37.0 (17.0, 77.0) 38.5 (21.0, 64.3) 45.0 (26.0, 84.0) 0.751 40.0 (21.0, 69.0) 43.5 (23.3, 74.0) 0.707 
Albumin, g/dL 4.2 ± 0.3 4.2 ± 0.3 4.2 ± 0.3 0.994 4.2 ±0.3 4.2 ±0.4 0.775 
Platelet, x10
9
/L 240 ± 57 231 ± 63 214 ± 71 0.002 229 ± 63 227 ± 70 0.529 
Glucose, mg/dL 101.0 (93.0, 113.0) 104.0 (95.0, 121.3) 107.0 (95.0 135.0) 0.005 105.0 (95.0, 122.0) 101.0 (93.3, 116.8) 0.035 
Insulin, μIU/mL 11.0 (8.3, 15.2) 11.5 (8.1, 18.2) 12.7 (9.3, 19.3) 0.061 11.4 (8.2, 16.9) 12.4 (9.3, 20.3) 0.014 
HOMA-IR 2.74 (1.98, 4.18) 3.05 (2.06, 4.96) 3.85 (2.40, 5.53) 0.016 3.13 (2.14, 4.65) 3.14 (2.25, 5.41) 0.191 
Adipose-IR 7157 (4930, 11248) 6686 (4062, 22613) 8706 (5023, 14715) 0.048 7191 (4478, 12140) 7346 (5307, 12913) 0.578 
hsCRP, mg/dL 0.8 (0.4, 2.2) 0.9 (0.5, 2.3) 1.3 (0.7, 2.4) 0.080 0.9 (0.5, 2.3) 1.2 (0.6, 2.2) 0.954 
Diabetes, N (%) 40 (33.6) 82 (38.3) 50 (39.4) 0.671 151 (38.4) 21 (30.9) 0.755 
Obesity (BMI ≥ 25), N (%) 76 (63.9) 138 (64.5) 92 (73.0) 0.060 262 (66.8) 44 (64.7) 0.865 
Metabolic syndrome, N (%) 80 (67.2) 140 (66.7) 92 (73.0) 0.436 266 (68.2) 46 (69.7) 0.758 
２４ 
 
The data are expressed as the means ± standard deviations or medians (interquartile ranges). 
1
From ANOVA or binary logistic regression analysis with adjustment for age and sex 
Abbreviations: BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; HOMA-IR, homeostasis model assessment of insulin 
resistance; Adipo-IR, adipose tissue insulin resistance; hsCRP, high sensitivity C-reactive protein. 
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 Next, we counted risk alleles at PNPLA3 rs738409 (by coding 0, 1, and 2 for 
CC, CG, and GG genotypes, respectively) and TM6SF2 rs58542926 (by 
coding 0, 1, and 2 for CC, CT, and TT genotypes, respectively) for each 
subject, and investigated whether PNPLA3 and TM6SF2 variants exerted an 
additive effect on the histological severity of NAFLD. Among NAFLD 
subjects, as the number of risk alleles increased, the prevalence of NASH 
increased; it was 28.2%, 41.8%, 63.7%, and 69.2% in subjects with 0, 1, 2, 
and 3 risk alleles, respectively (P for trend < 0.001; Figure 5a). The risk of 
NASH significantly increased even after adjustment for age and sex (OR per 
risk allele, 2.04; 95% CI, 1.54–2.71; Model 2 in Table 10). Prevalence of 
significant fibrosis also increased as the number of risk alleles increased; 
specifically, it was 22.5%, 28.8%, 43.7%, and 61.5% in subjects with 0, 1, 2, 
and 3 risk alleles, respectively (age and sex-adjusted OR per risk allele, 1.67; 
95% CI, 1.25–2.23; Model 2 in Table 10 and Figure 5b). With additional 
adjustment for HOMA-IR and hsCRP, the additive effects of PNPLA3 
rs738409 and TM6SF2 rs58542926 on the risk of NASH and significant 
fibrosis were maintained (Model 4 in Table 9). After stratification according 
to insulin resistance, the prevalence of NASH and significant fibrosis 
significantly increased with increasing number of risk alleles, even in subjects 
with low insulin resistance (age and sex-adjusted P for trend = 0.008 and 






Figure 5. Additive effects of PNPLA3 and TM6SF2 genetic variants on the 
risk of NASH and significant fibrosis in subjects with NAFLD 
 
Prevalence of NASH (a) and significant fibrosis (b) among NAFLD subjects according 
to the total number of risk alleles is shown. Risk alleles were counted and summed in 
an additive model at PNPLA3 rs738409 (by coding 0, 1, and 2 for CC, CG, and GG 
genotypes, respectively) and in a dominant model at TM6SF2 rs58542926 (by coding 
0, 1, and 2 for CC and CT/ TT genotypes, respectively) for each subjects. As the 
number of risk alleles increased, the prevalence of NASH (a) and significant fibrosis (b) 
increased (P for trend < 0.001 and P for trend = 0.001, respectively), even after 
adjustment for age and sex. A significantly increasing trend in the prevalence of 
NASH (c) and significant fibrosis (d) according to the number of risk alleles was 
observed in both subjects with low insulin resistance (P for trend = 0.008 and 0.020, 
respectively; closed circles) and subjects with insulin resistance (P for trend < 0.001 
an P for trend = 0.005, respectively; closed squares).  




Table 10. Additive effect of PNPLA3 rs738409 and TM6SF2 rs58542926 on the risk of NASH and significant fibrosis in 
subjects with NAFLD 
 
 
Model 1 Model 2 Model 3 Model 4 
OR (95% CI) P- value OR (95% CI) P- value OR (95% CI) P- value OR (95% CI) P- value 
Odds ratio for NASH in NAFLD subjects       
No risk allele  (reference)  (reference)  (reference)  (reference)  
1 risk allele  1.83 (0.99, 3.38) 0.053 1.85 (0.99, 3.44) 0.052 2.02 (1.07, 3.81) 0.030 2.03 (1.05, 3.90) 0.034 
2 risk alleles  4.48 (2.34, 8.36) <0.001 4.30 (2.28, 8.09) <0.002 4.45 (2.34, 8.49) <0.001 4.39 (2.25, 8.54) <0.001 
3 risk alleles  5.74 (1.59, 20.77) 0.008 6.01 (1.63, 22.15) 0.007 8.33 (2.13, 32.60) 0.002 5.89 (1.45, 24.01) 0.013 
          
Per risk gene  2.08 (1.57, 2.75) <0.001 2.04 (1.54, 2.71) <.001 2.11 (1.58, 2.81) <0.001 2.03 (1.50, 2.73) <0.001 
          
Odds ratio for Significant fibrosis in NAFLD subjects       
No risk allele  (reference)  (reference)  (reference)  (reference)  
1 risk allele  1.39 (0.72, 2.69) 0.332 1.52 (0.77, 3.01) 0.232 1.65 (0.82, 3.32) 0.157 1.62 (0.80, 3.30) 0.180 
2 risk alleles  2.67 (1.39, 5.12) 0.003 2.49 (1.27, 4.88) 0.008 2.55 (1.29, 5.07) 0.007 2.39 (1.19, 4.80) 0.014 
3 risk alleles  5.50 (1.58, 19.17) 0.007 6.09 (1.67, 22.17) 0.006 7.87 (2.10, 29.46) 0.002 5.82 (1.52, 22.27) 0.010 
          
Per risk gene  1.74 (1.31, 2.31) <0.001 1.67 (1.25, 2.23) 0.001 1.70 (1.27, 2.29) <0.001 1.61 (1.19, 2.17) 0.002 
          
 
The number of the risk allele is the sum of the G allele at rs738409 as an additive model and that of the T allele at rs58542926 as a dominant 
model. 
 
Model 1, without adjustment 
Model 2, with adjustment for age and sex 
Model 3, with adjustment for age, sex, and HOMA-IR 
28 
 
Model 4, with adjustment for age, sex, HOMA-IR, and hsCRP 
 
Abbreviations: NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; OR, odds ratio; CI, confidence interval; HOMA-






In this cross-sectional analysis of a prospective cohort consisting of biopsy-
proven NAFLD subjects, we replicated the significant associations between 
NASH and both PNPLA3 rs738409 and TM6SF2 rs58542926 genetic variants. 
Although the associations between NASH and typical metabolic phenotypes, 
such as metabolic syndrome, obesity, and diabetes, were attenuated among 
NAFLD subjects because these metabolic phenotypes were frequently noticed 
even in NAFL subjects, the identification of risk variants in PNPLA3 and 
TM6SF2 as well as insulin resistance was useful for detecting NASH or 
significant fibrosis among NAFLD subjects. Although the associations 
between NASH and genetic variants of in PNPLA3 and TM6SF2 had been 
previously established,
8-12
 we newly found that these relationships were 
maintained even after adjustment for metabolic syndrome and insulin 
resistance. 
 Genetic susceptibility might explain the relatively higher prevalence of 
NAFLD the lower BMI in Asian populations, the prevalence of NAFLD 
among the non-obese Asian is 15–21%.
33,34
 The MAF of PNPLA3 rs738409 is 
0.3–0.5 in the Asian population,
35,36
 which is significantly higher than that in 
the Western population (0.22),
8
 suggesting that genetic susceptibility rather 
than metabolic risk factors might play an important role in the development of 
NAFLD in the Asian population. It has been confirmed that PNPLA3 





 Our study provided robust evidence of the importance 
of genetic variants in predicting the occurrence as well as the progression of 
NAFLD in terms of the histological severity. 
 In terms of genetic determinants of fibrosis in NAFLD, we replicated the 
significant associations between fibrosis and PNPLA3 rs738409.
8-10
 In the 
case of TM6SF2 rs58542926, there have been conflicting data on that: 
although earlier studies reported that T allele significantly increased the risk 
of fibrosis in biopsy-proven NAFLD subjects,
37,38
 following studies did 
not.
12,39
 Different ethnicities or clinical characteristics of the study subjects 
might affect the association. Sookoian et al. showed no association between 
TM6SF2 rs58542926 and fibrosis in Caucasian NAFLD subjects (n = 226).
12
 
The mean BMI of that study subjects were > 31 kg/m
2
, which was higher than 
those in our study subjects (NAFL, 26.9 kg/m
2
; NASH, 27.7 kg/m
2
). Akuta et 
al. also reported a negative result using Asian NAFLD subjects with similar 
BMI; however, they analyzed the genetic effect using only 140 NAFLD 
subjects. In the current study, using 416 biopsy-proven subjects, we found the 
significant association between rs58542926 C > T and the significant fibrosis 
even after adjustment for confounders including insulin resistance and obesity. 
Further large scaled studies are needed to elucidate the effects of TM6SF2 
variants on hepatic fibrosis in NAFLD subjects with diverse ethnic and 
clinical backgrounds. 
 We additionally examined the relationships between metabolic traits and 
genetic variants and we found significant trends towards higher HOMA-IR 
and adipo-IR as the number of G alleles increased at PNPLA3 rs738409, even 
３１ 
 
in subjects without NAFLD. However, TM6SF2 rs58542926 was not 
associated with insulin resistance, which suggests that PNPLA3 and TM6SF2 
might play different roles in the pathogenesis of NAFLD. A limited number 
of studies have examined the mechanism by which these variants affect the 
risk of NASH. Previous studies reported that PNPLA3 rs738409 was not 
associated with insulin resistance
8
 of other metabolic traits such as BMI, lipid 
levels, and diabetes.
40
 Some differences in baseline characteristics of the study 
subjects may account for this discrepancy between previous and our studies. 
Previous studies mainly included African-Americans and European-
Americans, with mean BMI 27–34 kg/m
2
, in a cohort of patients with 
cardiovascular disease.
8,40
 In the current study, the control subjects were of 
Asian ethnicity and had lower BMI (median, 23.8 kg/m
2
) and HOMA-IR 
(median, 2.03). Further studies are warranted to elucidate the effects of 
PNPLA3 variants on systemic insulin resistance in ethnic populations with 
diverse metabolic profiles. Some evidence suggests that PNPLA3 is associated 
with insulin signaling or lipid metabolism.
9,41
 Histological data obtained from 
NAFLD subjects have indicated that the expression levels of insulin receptor, 
steroid regulatory element binding protein 1c, and peroxisome proliferator-
activated receptor-α are decreased in subjects with the GG genotype at 
rs738409.
9
 An in vitro study had recently shown that PNPLA3 promotes the 
hydrolysis of retinyl palmitate in human hepatic stellate cells in response to 
insulin,
41
 which was markedly reduced in PNPLA3 148M as compared to 
148I.
41
 By contrast, TM6SF2 rs58542926 C>T may alter microsomal 
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triglyceride transfer protein expression, resulting in the alteration of the 
packing and export of triglycerides,
42
 rather than insulin signaling. 
 Given the independent pathways involved in the development of hepatic 
steatosis by PNPLA3
8,9,41
 and TM6SF2 variants,
42
 PNPLA3 and TM6SF2 
might increase the risk of NASH complementarily. We confirmed the additive 
effects of PNPLA3 and TM6SF2 on the histological severity of NAFLD, even 
after adjustment for insulin resistance and systemic inflammation. Previous 
studies have also shown an additive effect of both variants on NAFLD 
risk;
43,44
 however, the association was demonstrated using only radiologic 
imaging studies.
43,44
 Our study was based on the histologic severity by liver 
biopsy and histologic diagnoses of NASH and significant fibrosis were 
reviewed and established by pathologist who specializes in liver pathology. 
The main strength of this study was that we comprehensively investigated 
the impact of genetic variants along with clinical risk factors on the 
histological severity of NAFLD using a large prospective biopsy-proven 
cohort (n = 525), which is exceptional in studies on the Asian population. 
Additionally, we confirmed the independent associations between genetic 
variants and the histological severity of NAFLD after adjustment for a variety 
of clinical confounders, including insulin resistance (HOMA-IR) and 
inflammatory markers (hsCRP). 
One limitation of this study was the inability to infer the causality of the 
observed relationships owing to the cross-sectional nature of the study. 
Second, the conclusions might not be generalizable to other ethnic groups. 
In conclusion, we replicated the significant associations between histological 
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severity of NAFLD and PNPLA3 rs738409 and TM6SF2 rs58542926 genetic 
variants. We also found distinct differences in the metabolic profiles among 
genetic variants and confirmed the additive effects of PNPLA3 and TM6SF2 
on the risks of NASH and significant fibrosis. Further mechanistic studies are 
warranted to elucidate the metabolic functions of proteins encoded by mutant 
genes and large-scale longitudinal cohort studies are needed to develop a 
novel risk- or outcome-prediction model comprising diverse metabolic 
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서론: 최근 다양한 인종의 그룹에서 PNPLA3 와 TM6SF2 유전자 
변이가 비알코올 지방간 환자와 관련되어 있다는 유전체 연구가 
발표되었다. 그러나 동양인 비알코올 지방간 환자에서의 유전적 
영향에 관한 자료는 부족한 상태이다. 따라서 본 연구는 동양인 
비알코올 지방간 환자의 조직학적 정도 및 대사 표현형에 
따른 PNPLA3 와 TM6SF2 유전자 변이의 영향을 알아보고자 
하였다. 
방법: 조직검사로 비알코올 지방간을 진단 받은 525 명의 
환자군에서 PNPLA3 rs738409 와 TM6SF2 rs58542926 의 
유전자형을 분석하였다.  
결과: PNPLA3 rs738409 와 TM6SF2 rs58542926 는 지방간염뿐 
아니라 F2 이상의 간 섬유화와 상관 관계가 있었으며 이는 대사 
위험 인자를 고려하였을 때에도 동일한 결과가 나타났다. 그러나 두 
개의 유전체 변이 중 rs738409 만이 HOMA-IR 과 adipo-IR 과 
유의한 상관 관계를 보였다. 그 밖에 PNPLA3 와 TM6SF2 는 
지방간염과 F2 이상의 간 섬유화의 위험성에 부가효과를 보였다.  
결론: PNPLA3 rs73840 와 TM6SF2 rs58542926 는 지방간염과 
F2 이상의 간 섬유화와 관련 되어있으며 위험성을 증가 시킨다.  
------------------------------------- 
주요어: 비알코올 지방간, 비알코올 지방간염, 인슐린 저항성, 
PNPLA3, TM6SF2 
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